Status:
NOT_YET_RECRUITING
Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
Lead Sponsor:
Changhai Hospital
Conditions:
Oligo-metastatic Prostate Carcinoma
Eligibility:
MALE
18-75 years
Phase:
NA
Brief Summary
The existing large prospective study demonstrates the benefits of primary radiotherapy in patients with low-volume oligo-metastatic prostate cancer (OMPC), and there is also more evidence of the benef...
Detailed Description
This study involves a single-center, limited-sample, single-arm exploration of radiotherapy for prostate and oligo-metastatic lesions in patients diagnosed with low-volume, hormone-sensitive OMPC. Eli...
Eligibility Criteria
Inclusion
- Aged 18 years or over at the time of registration
- Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;
- Histologically confirmed prostate adenocarcinoma via prostate biopsy;
- Assessment conducted via single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and Ga-68 prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography(PET/CT), revealing oligo-metastasis (involving \< 4 metastatic lesions in non-pelvic lymph nodes and bones) with or without pelvic lymph node involvement;
- Expected survival duration \>2 years.
- The willingness of patients to voluntarily accept the experimental research protocol after being informed of existing treatment options.
Exclusion
- Any previous or ongoing treatment for prostate cancer, including radiotherapy, chemotherapy, focal treatment, etc.
- Pathology indicating small-cell or neuroendocrine tumor components;
- Patients with visceral metastases, or ≥4 metastases;
- Patients with concurrent malignancies or those in an acute infection period or severe infection state; patients positive for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and/or syphilis (Treponema pallidum)
- Severe or active systemic comorbidities that, in the investigator's judgment, might interfere with the treatment, evaluation, and compliance of this trial, including severe conditions affecting respiratory, circulatory, nervous, mental, digestive, endocrine, immune, urological, and other systems;
- Individuals with contraindications related to radiation therapy may present heightened risks of treatment-related complications.
- Patients participating in other clinical trials;
- Patients unsuitable for participation in this clinical trial as per the judgement of the investigator.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06198387
Start Date
January 1 2024
End Date
September 1 2028
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433